|60mg × 30 pillole||$2.76||$82.91||+ Levitra||Aggiungi al carello|
|60mg × 60 pillole||$2.24||$134.47||$31.35||+ Cialis||Aggiungi al carello|
|60mg × 90 pillole||$2.07||$186.03||$62.7||+ Viagra||Aggiungi al carello|
|60mg × 120 pillole||$1.98||$237.59||$94.05||+ Levitra||Aggiungi al carello|
Ralista (Raloxifene hydrochloride) is a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. Raloxifene's biological actions are largely mediated through binding to estrogen receptors. This binding results in activation of certain estrogenic pathways and blockade of others. Thus, raloxifene is a selective estrogen receptor modulator (SERM).
The recommended dosage is one 60-mg Ralista tablet daily, which may be administered any time of day without regard to meals.
Use the medicine as prescribed by your doctor.
If you miss a dose of Ralista, skip the missed dose and go back to the regular dosing schedule. Do not take 2 doses at once.
Store Ralista at 77 degrees F (25 degrees C), in a tightly closed container. Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Ralista out of the reach of children and away from pets.
Active Ingredient: Raloxifene
Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to the premenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of bone turnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in bone mineral density (BMD) and decreases in incidence of fractures. Raloxifene also has effects on lipid metabolism. Raloxifene decreases total and LDL cholesterol levels but does not increase triglyceride levels. It does not change total HDL cholesterol levels. Preclinical data demonstrate that raloxifene is an estrogen antagonist in uterine and breast tissues. Clinical trial data (through a median of 42 months) suggest that raloxifene lacks estrogen-like effects on the uterus and breast tissue.
Ralista is contraindicated in lactating women or women who are or may become pregnant. It may cause fetal harm when administered to a pregnant woman. Ralista is also contraindicated in women with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, retinal vein thrombosis and in women known to be hypersensitive to raloxifene or other constituents of the tablets.
In clinical trials, raloxifene treated women had an increased risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism). Other venous thromboembolic events could also occur. A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene. The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first 4 months of treatment, and the magnitude of risk appears to be similar to the reported risk associated with use of hormone replacement therapy. Because immobilization increases the risk for venous thromboembolic events independent of therapy, Ralista should be discontinued at least 72 hours prior to and during prolonged immobilization (e.g., post-surgical recovery, prolonged bed rest), and Ralista therapy should be resumed only after the patient is fully ambulatory. In addition, women taking Ralista should be advised to move about periodically during prolonged travel. The risk-benefit balance should be considered in women at risk of thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis and active malignancy.
Ralista has not been associated with endometrial proliferation. Unexplained uterine bleeding should be investigated as clinically indicated.
Ralista has not been associated with breast enlargement, breast pain, or an increased risk of breast cancer. Any unexplained breast abnormality occurring during Ralista therapy should be investigated.
History of Breast Cancer
Ralista has not been adequately studied in women with a prior history of breast cancer.
Since negligible amounts of raloxifene and eliminated in urine, a study in patients with renal insufficiency was not conducted. In the osteoporosis treatment and prevention trials, raloxifene and metabolite concentrations in women with estimated creatinine clearance as low as 21 mL/min are similar to women with normal creatinine clearance.
Raloxifene was studied, as a single dose, in Child-Pugh Class A patients with cirrhosis and total serum bilirubin ranging from 0.6 to 2.0 mg/dL. Plasma raloxifene concentrations were approximately 2.5 times higher than in controls and correlated with bilirubin concentrations. Safety and efficacy have not been evaluated further in patients with hepatic insufficiency (see WARNINGS).
Pregnancy Category X -- Ralista should not be used in women who are or may become pregnant.
Ralista should not be used by lactating women . It is not known whether raloxifene is excreted in human milk.
Ralista should not be used in pediatric patients.
Use in elderly
In the osteoporosis treatment trial of 7705 postmenopausal women, 4621 women were considered geriatric (greater than 65 years old). Of these, 845 women were greater than 75 years old. Safety and efficacy in older and younger postmenopausal women in the osteoporosis treatment trial appeared to be comparable.
Use in Men
Safety and efficacy have not been evaluated in men.
The safety of raloxifene in the treatment of osteoporosis was assessed in a large (7705 patients) multinational placebo-controlled trial. Common adverse events considered to be related to raloxifene therapy were hot flashes and leg cramps. The majority of adverse events occurring during the study were mild and generally did not require discontinuation of therapy. These adverse events included infection, migraine, nausea, myalgia, insomnia, rash, conjunctivitis, vaginitis.
Incidents of overdose in humans have not been reported. In an 8-week study of 63 postmenopausal women, a dose of raloxifene HCl 600 mg/day was safely tolerated. No mortality was seen after a single oral dose in rats or mice at 5000 mg/kg (810 times the human dose for rats and 405 times the human dose for mice based on surface area, mg/m 2) or in monkeys at 1000 mg/kg (80 times the AUC in humans). There is no specific antidote for raloxifene.